SIB 1893CAS# 6266-99-5 |
- PHA-665752
Catalog No.:BCC1181
CAS No.:477575-56-7
- (R)-Crizotinib
Catalog No.:BCC1284
CAS No.:877399-52-5
- Tivantinib (ARQ 197)
Catalog No.:BCC3688
CAS No.:905854-02-6
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 6266-99-5 | SDF | Download SDF |
| PubChem ID | 5311432 | Appearance | Powder |
| Formula | C14H13N | M.Wt | 195.26 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 2-methyl-6-[(E)-2-phenylethenyl]pyridine | ||
| SMILES | CC1=CC=CC(=N1)C=CC2=CC=CC=C2 | ||
| Standard InChIKey | SISOFUCTXZKSOQ-ZHACJKMWSA-N | ||
| Standard InChI | InChI=1S/C14H13N/c1-12-6-5-9-14(15-12)11-10-13-7-3-2-4-8-13/h2-11H,1H3/b11-10+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | A highly selective non-competitive antagonist for the metabotropic glutamate mGlu5 receptor subtype; displays an IC50 value of 0.3 μM at hmGlu5, compared with > 100 μM at hmGlu1b, hmGlu2, hmGlu6, hmGlu7 and hmGlu8. Centrally active upon systemic administration in vivo. Positive allosteric modulator at mGlu4 receptors. |
SIB 1893 Dilution Calculator
SIB 1893 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 5.1214 mL | 25.6069 mL | 51.2138 mL | 102.4275 mL | 128.0344 mL |
| 5 mM | 1.0243 mL | 5.1214 mL | 10.2428 mL | 20.4855 mL | 25.6069 mL |
| 10 mM | 0.5121 mL | 2.5607 mL | 5.1214 mL | 10.2428 mL | 12.8034 mL |
| 50 mM | 0.1024 mL | 0.5121 mL | 1.0243 mL | 2.0486 mL | 2.5607 mL |
| 100 mM | 0.0512 mL | 0.2561 mL | 0.5121 mL | 1.0243 mL | 1.2803 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Ro 106-9920
Catalog No.:BCC7175
CAS No.:62645-28-7
- 11S,12-Dihydroxyspirovetiv-1(10)-en-2-one
Catalog No.:BCN1391
CAS No.:62623-86-3
- (+)-Mellein
Catalog No.:BCN7220
CAS No.:62623-84-1
- 4,6,7-Trimethoxy-5-methylcoumarin
Catalog No.:BCN4166
CAS No.:62615-63-8
- 2',4'-Dihydroxy-3'-methoxyacetophenone
Catalog No.:BCN7535
CAS No.:62615-26-3
- Oxiracetam
Catalog No.:BCC5447
CAS No.:62613-82-5
- H-HoCys-OH
Catalog No.:BCC3231
CAS No.:626-72-2
- 2,4-Dihydroxypyridine
Catalog No.:BCC8500
CAS No.:626-03-9
- Neocyclomorusin
Catalog No.:BCN3601
CAS No.:62596-35-4
- Cyclomorusin
Catalog No.:BCN4610
CAS No.:62596-34-3
- Morusin
Catalog No.:BCN4165
CAS No.:62596-29-6
- 11R,12-Dihydroxyspirovetiv-1(10)-en-2-one
Catalog No.:BCN1392
CAS No.:62574-30-5
- 1-Hydroxy-2-methylanthraquinone
Catalog No.:BCN3478
CAS No.:6268-09-3
- Handelin
Catalog No.:BCN2953
CAS No.:62687-22-3
- Saikosaponin F
Catalog No.:BCN2776
CAS No.:62687-63-2
- H-D-Arg-OH.HCl
Catalog No.:BCC2869
CAS No.:627-75-8
- Dioctanoylglycol
Catalog No.:BCC6662
CAS No.:627-86-1
- NF 449
Catalog No.:BCC7043
CAS No.:627034-85-9
- Dihydrolycorine
Catalog No.:BCN2475
CAS No.:6271-21-2
- SKF38393 HCl
Catalog No.:BCC6526
CAS No.:62717-42-4
- 4-Amino-N-methylbenzamide
Catalog No.:BCC8685
CAS No.:6274-22-2
- BMS-564929
Catalog No.:BCC1425
CAS No.:627530-84-1
- SD-208
Catalog No.:BCC1938
CAS No.:627536-09-8
- Epitrametol
Catalog No.:BCN7073
CAS No.:627538-65-2
Influence of SIB 1893, a selective mGluR5 receptor antagonist, on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy.[Pubmed:14704469]
Pol J Pharmacol. 2003 Sep-Oct;55(5):735-40.
SIB 1893, a non-competitive antagonist of group I metabotropic glutamate receptor subtype 5, administered at doses ranging from 0.25 to 10 mg/kg, failed to influence pentetrazole-induced convulsions in mice. Moreover, SIB 1893 (10 and 20 mg/kg) did not affect the protective action of valproate, ethosuximide, phenobarbital and clonazepam in this test. Similarly, the mGluR5 antagonist did not modulate the antiseizure activity of carbamazepine, diphenylhydantoin and phenobarbital against maximal electroshock in mice. The combined treatment of SIB 1893 with conventional antiepileptic drugs did not lead to motor impairment. Long-term memory disturbances were observed only in the case of the combination of SIB 1893 with phenobarbital.
SIB 1893, a selective mGluR5 receptor antagonist, potentiates the anticonvulsant activity of oxcarbazepine against amygdala-kindled convulsions in rats.[Pubmed:15520501]
Pol J Pharmacol. 2004 Jul-Aug;56(4):459-64.
SIB 1893 (a non-competitive antagonist of group I metabotropic glutamate receptors), given at 40 mg/kg (but not at 20-30 mg/kg), shortened the afterdischarge duration in amygdala-kindled rats, being ineffective on other seizure parameters - seizure severity, seizure duration, and afterdischarge threshold. Oxcarbazepine (at 7.5 mg/kg, but not at 5 mg/kg), a newer antiepileptic drug, reduced seizure severity, seizure and afterdischarge durations. When combined at ineffective doses in amygdala kindling, SIB 1893 at 20 or 30 mg/kg and oxcarbazepine at 5 mg/kg, significantly reduced seizure and afterdischarge durations. The results indicate that combinations of oxcarbazepine with antagonists of group I metabotropic glutamate receptors may offer a novel therapeutic approach in cases of drug-resistant epilepsy.
Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP.[Pubmed:12684257]
Br J Pharmacol. 2003 Mar;138(6):1026-30.
We have identified 2-methyl-6-(2-phenylethenyl)pyridine (SIB-1893) and 2-methyl-6-phenylethynyl pyridine hydrochloride (MPEP) as positive allosteric modulators for the hmGluR4. SIB-1893 and MPEP enhanced the potency and efficacy of L-2-amino-4-phophonobutyrate (L-AP4) in guanosine 5'-O-(3-[(35)S]thiotriphosphate ([(35)S]GTPgammaS) binding and efficacy in cAMP studies. These effects were fully blocked by the mGluR4 competitive antagonist (RS)-alpha-cyclopropyl-4-phosphonophenylglycine (CPPG), indicating a dependency on receptor activation. Although SIB-1893 and MPEP had no effects alone in GTPgammaS binding, effects were observed in the cell-based cAMP assay due to media-derived activation as indicated by CPPG inhibition. Positive modulation of the mGluR4 was a receptor-specific effect since SIB-1893 and MPEP had neither effects on mGluR2-expressing cells nor on the parent BHK cell line. In [(3)H]L-AP4 binding, a two-fold decrease in K(D) but not in B(max) was observed with 100 micro M SIB-1893, whereas MPEP affected neither parameter. Finally, SIB-1893 and MPEP failed to displace [(3)H]L-AP4 binding. Taken together, these data identify positive allosteric modulators for the hmGluR4.
Non-competitive metabotropic glutamate subtype 5 receptor antagonist (SIB-1893) decreases body temperature in rats.[Pubmed:16382199]
Pharmacol Rep. 2005 Nov-Dec;57(6):795-801.
This study examined the effect of (E)-2-methyl-6-(2-phenylethynyl)-pyridine (SIB-1893), a selective non-competitive metabotropic glutamate subtype 5 receptor (mGluR5) antagonist, on body temperature in freely moving Wistar rats. Temperature was monitored using programmed microchips, implanted subcutaneously in rats, at several times: 0, 5, 10, 20, 30, 45, 60, 90, 120 and 180 min after intraperitoneal administration of SIB-1893 at increasing doses of 10, 20 and 30 mg/kg. The results analyzed with two-way ANOVA with repeated measures on time revealed that SIB-1893 at 30 mg/kg considerably lowered the body temperature in animals at 90, 120 and 180 min after its systemic injection. In contrast, the drug at 10 and 20 mg/kg remained without effect on the body temperature in rats. Based on our preclinical study, one can conclude that SIB-1893 produces hypothermia in freely moving rats in a dose-dependent manner.
